Searchable abstracts of presentations at key conferences in endocrinology

ea0073pep10.2 | Presented ePosters 10: Thyroid | ECE2021

Graves’ disease and concurrent immune thrombocytopenia in a patient with albinism following alemtuzumab treatment for multiple sclerosis: a rare case report

Daraki Vasiliki , Eleni-Konstantina Syntzanaki , Mastorodemos Vasileios , Kontolaimaki Kalliopi , Mytilinaiou Maria , Chrysoulaki Maria , Sfakiotaki Maria , Betsi Grigoria , Xekouki Paraskevi

IntroductionAlemtuzumab is an anti-CD52 antibody, leading to lysis and transient depletion of T and B lymphocytes. Its therapeutic effect is mediated by the alteration in immune repertoire that accompanies subsequent lymphocyte reconstitution. It is mainly used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Common side effects are autoimmune diseases, including thyroid disease (>40%), immune thrombocytopenia (IT...

ea0073aep13 | Adrenal and Cardiovascular Endocrinology | ECE2021

Epidemiology, clinical course, and genetic analysis of pheochromocytomas/paragangliomas: A single centre tertiary care experience over 16 years from crete-greece

Chrysoulaki Maria , Fostira Florentia , Daraki Vasiliki , Betsi Grigoria , Sfakiotaki Maria , Mytilinaiou Maria , Bouki Katerina , Stathias Konstantinos , Spanakis Konstantinos , Panagiotis-Nikolaos Tsakalomatis , Eleni-Konstantina Syntzanaki , Kontolaimaki Kalliopi , Vamvoukaki Rodanthi , Nastos Konstantinos , Xekouki Paraskevi

BackgroundPheochromocytomas (PHOEs) and paragangliomas (PGLs) are rare neuroendocrine tumors originating from chromaffin cells. PHEO/PGL incidence ranges between 2–8/million, with 10–49% of these tumors being detected incidentally during imaging performed for other reasons. Up to 40% of PHEOs/PGLs patients have disease-specific germline pathogenic variants. This study aimed to investigate the epidemiology, clinical course, and genetic backgroun...